关于CYP2D6抑制在他莫昔芬治疗决策中的作用的证据与实践。 - Suppr

Suppr

超能文献

Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy.

作者信息

Lash Timothy L, Rosenberg Carol L

出版信息

J Clin Oncol. 2010 Mar 10;28(8):1273-5. doi: 10.1200/JCO.2009.26.7906. Epub 2010 Feb 1.

DOI:10.1200/JCO.2009.26.7906

PMID:20124162

Abstract

摘要

相似文献

Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy.关于CYP2D6抑制在他莫昔芬治疗决策中的作用的证据与实践。

J Clin Oncol. 2010 Mar 10;28(8):1273-5. doi: 10.1200/JCO.2009.26.7906. Epub 2010 Feb 1.

The ethics of CYP2D6 testing for patients considering tamoxifen.考虑使用他莫昔芬的患者进行CYP2D6检测的伦理学问题。

Breast Cancer Res. 2007;9(2):103. doi: 10.1186/bcr1663.

Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.CYP2D6基因多态性与他莫昔芬在乳腺癌女性中的临床意义

Clin Adv Hematol Oncol. 2008 Nov;6(11):825-33.

CYP2D6 genotype and tamoxifen response.细胞色素P450 2D6基因分型与他莫昔芬反应

Breast Cancer Res. 2005 Jul 29;7(5):E6. doi: 10.1186/bcr1297.

Update on CYP2D6 and Tamoxifen.

Clin Adv Hematol Oncol. 2013 Mar;11(3):178-80.

CYP2D6 variants and the prediction of tamoxifen response in randomized patients: author response.CYP2D6基因变异与随机分组患者中他莫昔芬反应的预测：作者回应

Breast Cancer Res. 2005 Mar 29;7(6):E7. doi: 10.1186/bcr1326.

Do some antidepressants decrease effect of tamoxifen?某些抗抑郁药会降低他莫昔芬的疗效吗？

J Support Oncol. 2009 Jul-Aug;7(4):147-8.

Gene testing to tailor breast cancer therapy has arrived--is it ready for the clinic?

J Natl Cancer Inst. 2008 Aug 6;100(15):1050-1. doi: 10.1093/jnci/djn286. Epub 2008 Jul 29.

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.CYP2D6基因分型和抑制剂对他莫昔芬代谢的定量影响：对优化乳腺癌治疗的启示

Clin Pharmacol Ther. 2006 Jul;80(1):61-74. doi: 10.1016/j.clpt.2006.03.013.

The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.CYP2D6*4 多态性影响他莫昔芬使用者的乳腺癌生存。

Breast Cancer Res Treat. 2009 Nov;118(1):125-30. doi: 10.1007/s10549-008-0272-2. Epub 2009 Feb 3.

引用本文的文献

Breast cancer recurrence in relation to antidepressant use.乳腺癌复发与抗抑郁药使用的关系。

Cancer Causes Control. 2016 Jan;27(1):125-36. doi: 10.1007/s10552-015-0689-y. Epub 2015 Oct 30.

Insurance coverage policies for personalized medicine.个性化医学的保险覆盖政策。

J Pers Med. 2012 Oct 30;2(4):201-16. doi: 10.3390/jpm2040201.

CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer.224名接受他莫昔芬辅助治疗的可手术乳腺癌菲律宾和越南女性的CYP2D6基因分型、内昔芬水平与疾病复发情况

Springerplus. 2013 Dec;2(1):52. doi: 10.1186/2193-1801-2-52. Epub 2013 Feb 15.

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.CYP2D6 和 UGT2B7 基因型与他莫昔芬治疗的乳腺癌患者复发风险。

J Natl Cancer Inst. 2012 Mar 21;104(6):452-60. doi: 10.1093/jnci/djs126. Epub 2012 Mar 6.

Delivering a pharmacogenetic service: is there a role for genetic counselors?提供药物遗传学服务：遗传咨询师能发挥作用吗？

J Genet Couns. 2012 Aug;21(4):527-35. doi: 10.1007/s10897-011-9415-4. Epub 2011 Nov 4.

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.他莫昔芬代谢物浓度、CYP2D6 基因型与乳腺癌结局。

Clin Pharmacol Ther. 2011 May;89(5):718-25. doi: 10.1038/clpt.2011.32. Epub 2011 Mar 23.

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.CYP2D6 抑制与丹麦基于人群研究中的乳腺癌复发。

J Natl Cancer Inst. 2011 Mar 16;103(6):489-500. doi: 10.1093/jnci/djr010. Epub 2011 Feb 15.

Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial.乳腺癌预防试验中基因组多态性与癌症风险相互作用的新型通路分析。

Int J Mol Epidemiol Genet. 2010;1(4):332-49. Epub 2010 Sep 5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验